# Helsinn

Source: https://onco.cc/companies/helsinn/  
OnCo record `helsinn` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Helsinn is a Swiss family-owned company focused on supportive cancer care: the antiemetics Aloxi and Akynzeo, and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma.

## Summary

Helsinn, a Swiss family-owned company based in Lugano, focuses on supportive cancer care with the antiemetics Aloxi and Akynzeo and the topical nitrogen mustard Valchlor for cutaneous T-cell lymphoma. It developed palonosetron, sold as Aloxi, and the netupitant and palonosetron fixed combination, sold as Akynzeo, for chemotherapy-induced nausea and vomiting, and acquired Valchlor, a mechlorethamine gel for mycosis fungoides, licensing its products to partners such as Eisai in the United States and Recordati in Europe. OnCo links it to palonosetron, netupitant and palonosetron, and mechlorethamine. Whether supportive care products can sustain an independent company as generics arrive is the open question. Each product has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Lugano
- Type: pharma
- Website: https://www.helsinn.com

## Sources

- Official website: https://www.helsinn.com

## Connected records

- drugs: [Infigratinib](https://onco.cc/drugs/infigratinib/), [Mechlorethamine (chlormethine)](https://onco.cc/drugs/mechlorethamine/), [Netupitant and palonosetron](https://onco.cc/drugs/netupitant-palonosetron/), [Palonosetron](https://onco.cc/drugs/palonosetron/)
- trials: [ROMANA 1 and ROMANA 2](https://onco.cc/trials/romana-1-2/), [Study 201](https://onco.cc/trials/study-201/), [Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)](https://onco.cc/trials/nct06904235/)
- key papers: [Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides](https://onco.cc/key-papers/paper-study-201-jama-dermatol-2013/)
- companies: [Recordati](https://onco.cc/companies/recordati/)

---
JSON: https://onco.cc/api/v1/entities/helsinn.json